氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T,Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T. LSR antibody therapy
inhibits ovarian epithelial tumor growth by inhibiting lipid uptake. Cancer Res. 2018 Jan 15;78(2):516-527.
②Sugase T, Takahashi T, Serada S, Fujimoto M, Hiramatsu K, Ohkawara T, Tanaka K, Miyazaki Y, Makino T,Kurokawa Y, Yamasaki M, Nakajima K, Kishimoto T, Mori M, Doki Y, Naka T.
SOCS1 gene therapy improves radiosensitivity and enhances irradiation-induced DNA damage in esophageal
squamous cell carcinoma. Cancer Res. 2017 Dec 15;77(24):6975-6986.

内科学講座

仲哲治

リウマチ・膠原病・教授

博士(医学)

アレルギー内科分野

臨床免疫学③Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T,

腫瘍学Naka T. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6
biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015 May;67(8):2056-60④Serada S, Fujimoto M, Ogata A, Terabe F, Hirano T, Iijima H, Shinzaki S, Nishikawa T, Ohkawara T, Iwahori K,Ohguro N, Kishimoto T, Naka T. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as anovel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis. 2010 Apr;69(4):770-4.
⑤Naka T, Narasaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K,Akira S, Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997 Jun26;387(6636):924-9.
① Tsukuda TK, Ohnishi H, Fujimoto M, Nakatani Y, Takamatsu K, Naka T, Yokoyama A. Lung CCR6-CXCR3- type 2
helper T cells as an indicator of progressive fibrosing interstitial lung diseases. Sci Rep. 2022;12(1):19577.
② Fujimoto M, Matsumoto T, Serada S, Tsujimura Y, Hashimoto S, Yasutomi Y, Naka T. Leucine-rich alpha 2
glycoprotein is a new marker for active disease of tuberculosis. Sci Rep. 2020;10(1):3384.
③ Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T. Leucine rich alpha-2 glycoprotein is a内科学講座

藤本穣

リウマチ・膠原病・アレルギー内科分野

准教授

博士(医学)

臨床免疫学

potential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun. 2018;498(4):1045-51.
④ Urushima H, Fujimoto M, Mishima T, Ohkawara T, Honda H, Lee H, Kawahata H, Serada S, Naka T. Leucine-richalpha 2 glycoprotein promotes Th17 differentiation and collagen-induced arthritis in mice through enhancement ofTGF-beta-Smad2 signaling in naive helper T cells. Arthritis Res Ther. 2017;19(1):137.
⑤ Fujimoto M, Serada S, Suzuki K, Nishikawa A, Ogata A, Nanki T, Hattori K, Kohsaka H, Miyasaka N, Takeuchi T,Naka T. Leucine-rich alpha2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6
biologic therapy in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(8):2056-60.

①Y Hosono, M Watanabe, M Sato et al. Multiple intra-articular injections with adipose-derived stem cells for knee
osteoarthritis cause severe arthritis with anti-histone H2B antibody production. Regen Ther. 2023;24:147-153.
②Hosono Y, Ishi A, Sato S et al. New Aspects of Clinical and Immunological Characteristics in Patients with Antiasparaginyl tRNA synthetase (anti-KS) Autoantibody. Mod Rheumatol. 2023;24:road011.
③Hosono Y, Sie B, Mammen AL et al. Coexisting autoantibodies against transcription factor Sp4 are associated
内科学講座

細野祐司

リウマチ・膠原病・with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies. Ann Rheum Dis

特任准教授

博士(医学)

臨床免疫学アレルギー内科分野

2022.
④ Hosono Y, Nakashima R, Mimori T et al. Splicing factor proline/glutamine-rich is a novel autoantigen ofdermatomyositis and associated with anti-melanoma differentiation-associated gene 5 antibody. J Autoimmun.
2017;77:116-122.
⑤ Casal-Dominguez M, Pinal-Fernandez I, Hosono Y, et al; Johns Hopkins Myositis Center Group. The indirect
immunofluorescence assay autoantibody profiles of myositis patients without known myositis-specificautoantibodies. Clin Exp Rheumatol. 2021;39:519-524①Murata O, Suzuki K, Takeuchi T, Kudo A. Incidence and baseline characteristics of relapse or exacerbation inpatients with pulmonary sarcoidosis in Japan. Sarcoidosis Vasc Diffuse Lung Dis. 2021; 38(3)e2021026②Murata O, Suzuki K, Sugiura H, Kondo Y, Takeshita M, Yasuoka H, Yamaoka K, Koga K, Morita R, Yoshimura A,Takeuchi T. Thymus variants on imaging in patients with rheumatoid arthritis—Clinical and immunologicalsignificance. Rheumatology (Oxford). 2021 Feb 16③Murata O, Sasaki N, Sasaki K, Kowada K, Ninomiya Y, Oikawa Y, Kobayashi H, Nakamura Y, Yamauchi K.

内科学講座

村田興則

リウマチ・膠原病・講師

博士(医学)

アレルギー内科分野

リウマチ・Detection of cerebral microvascular lesions using 7 T MRI in patients with neuropsychiatric systemic lupus

膠原病内科学

erythematosus. Neuroreport. 2015 Jan 7;26(1):27-32④Murata O, Izumi K, Kaneko Y, Yasuoka H, Suzuki K, Matsubara S, Yamaoka K, Takeuchi T. Microscopic
polyangiitis diagnosed by muscle specimen: a case report and literature review. Modern Rheumatology CaseReports. 2:2, 181-184⑤Sugai M, Murata O, Oikawa H, Katagiri H, Matsumoto A, Nagashima H, Sugai T, Maemondo M. A case of bonemarrow involvement in sarcoidosis with crescentic glomerular lesions. Respir Med Case Rep. 2020 Aug
28;31:101202①Suzuki Y, Kakisaka K, Sato T, Mikami R, Abe H, Sasaki T, Takikawa Y. Tc-99m GSA scintigraphy within the first 3
days after admission as an early predictor of outcome in severe acute liver injury. Sci Rep. 2021;11:12518.
②Suzuki Y, Kakisaka K, Suzuki A, Takahara T, Sasaki T, Sato T, Yonezawa T, Nitta H, Takikawa Y. A Lille model for
predicting the response of severe alcoholic hepatitis to corticosteroid treatment in Japanese patients. Hepatol Res.
2019;49:758-764

肝臓病学

内科学講座

鈴木悠地

リウマチ・膠原病・アレルギー内科分野

特任講師

博士(医学)③Sasaki T, Suzuki Y, Kakisaka K, Wang T, Ishida K, Suzuki A, Abe H, Sugai T, Takikawa Y. IL-8 induces

再生医療

transdifferentiation of mature hepatocytes toward the cholangiocyte phenotype. FEBS Open Bio. 2019;9:2105-

分子生物学

2116.
④Suzuki Y, Katagiri H, Wang T, Kakisaka K, Kume K, Nishizuka SS, Takikawa Y. Ductular reactions in the liver
regeneration process with local inflammation after physical partial hepatectomy. Lab Invest. 2016;96:1211-1222.
⑤2023年度科学研究助成事業(科研費)．基盤研究（C），研究代表者：鈴木悠地，研究期間：②2023-2025年度，動物個体の発生原理を利用した、異種間肝臓作製技術の開発

①Ito I, Nakaoka Y, Doi Y, et al. Primary Cardiac Lymphoma: A Lesson Learned from an Unsuccessful Experience.
Internal Medicine. 2018; 57(24): 3569-3574.
②伊藤いづみ, 中岡洋子, 土居義典, ほか. 心臓原発悪性リンパ腫. 別冊日本臨牀 循環器症候群（第3版）（Ⅲ）. 日本臨
牀社. (2019)

内科学講座

伊藤いづみ

リウマチ・膠原病・助教

学士(医学）

アレルギー内科分野

内科学一般関連③Ito I, Doi Y, et al. Primary Cardiac Lymphoma: Early Initiation of Chemotherapy is Critical to Save Lives of

循環器内科学関連

Patients. American College of Cardiology (ACC). March, 2017. Washington, DC, America.
④伊藤いづみ, 今井龍一郎, 土居義典, ほか. 上肢深部静脈血栓症の治療にCatheter-directed Thrombolysisが有効であった若年女性例, 第65回日本心臓病学会学術集会, 2017年9月, 大阪.
➄伊藤いづみ, 古島知樹, 北岡裕章, ほか. OCTとIVUSの画像所見が得られた特発性冠動脈解離の一例, 第24回日本心血管インターベンション治療学会 中国・四国地方会, 2017年9月, 岡山.
1. Lee H, Fujimoto M, Ohkawara T, Honda H, Serada S, Terada Y, Naka T. Leucine rich α-2 glycoprotein is apotential urinary biomarker for renal tubular injury. Biochem Biophys Res Commun 2018 Apr 15;498(4):1045-1051.
2 .Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Nishida T, Hirota S, Saito Y, Tanaka K,Miyazaki Y, Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanasaki K, Kishimoto T, Mori M, Doki Y, NakaT.SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through
FAK/PI3 K signaling.Gastric Cancer 2018 Nov;21(6):968-976.
3. Nakagawa S, Serada S, Kakubari R, Hiramatsu K, Sugase T, Matsuzaki S, Matsuzaki S, Ueda Y, Yoshino K,Ohkawara T, Fujimoto M, Kishimoto T, Kimura T, Naka T.

内科学講座

大河原知治

リウマチ・膠原病・助教

学士（医学）

膠原病内科学

Intratumoral delivery of an adenoviral vector carrying the SOCS-1 gene enhances Tcell-mediated anti-tumor
immunity by suppressing. Molecular Cancer Therapeutics 2018 Sep;17(9):1941-1950.

アレルギー内科分野

4. Sugase T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hiramatsu K, Koh M, Saito Y, Tanaka K, Miyazaki Y,
Makino T, Kurokawa Y, Yamasaki M, Nakajima K, Hanazaki K, Mori M, Doki Y, Naka T.Lipolysis-stimulated
lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutictarget in gastric cancer.Oncotarget 2018 Aug 31;9(68):32917-32928.
［和文］
1.大河原知治, 仲哲治 サイトカインの生理活性

免疫系

SOCSによる免疫制御

現況と展望 医学のあゆみ(0039-2359) 2004; 別冊サイトカイン-state of arts : 71-74.
① E. Funajima, G. Ito, E. Ishiyama, K. Ishida, T. Ozaki, Mitochondrial localization of calpain-13 in mouse brain,

内科学講座

舟嶋英志

リウマチ・膠原病・アレルギー内科分野

助教

修士 (理工学)

分子生物学

Biochem. Biophys. Res. Commun. 609 (2022) 149–155.
②舟嶋英志, 紺野真秀, 尾﨑拓 日本生化学会東北支部 第87回例会・シンポジウム「カルパイン-13の組織分布、細胞内局在および酵素学的性質」